tirzepatide vs dulaglutide in T2D with ASCVD | Scott Isaacs, MD, FACP, FACE posted on the topic Tirzepatide demonstrates cardiovascular protection in

Although it has not yet been reported, it is reasonable to expect that this defective GLP-1 secretion could be even more marked in women with PCOS and obesity

However, the principal strength of this study was the long-term observation, providing the first insights into a potential novel strategy for partially overcoming adaptive mechanisms following the cessation of semaglutide-induced weight loss in insulin-resistant populations

This is my second month on the product, and Im feeling wonderful, my weight loss has been great

Medicare's GLP-1 Bridge Program now offers eligible beneficiaries access to weight loss medications for a $50 monthly copay